Drug intelligence / Profile preview

LINE-1 retrotransposon vaccine

Development stage: Preclinical
Lead developer: Flag Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

Flag Bio is developing an mRNA-based cancer vaccine targeting proteins encoded by the Long Interspersed Nuclear Element-1 (LINE-1) retrotransposon. LINE-1 elements are mobile genetic sequences that are typically silenced in healthy somatic cells but become aberrantly activated and expressed in various types of cancer. By delivering mRNA that encodes LINE-1 proteins, the vaccine aims to stimulate the immune system to recognize and eliminate tumor cells expressing these neoantigens. This therapeutic candidate is currently in the preclinical stage of development.

Other names: LINE-1 mRNA vaccineLINE1 mRNA vaccineLINE 1 mRNA vaccineFlag Bio LINE-1 vaccine

Targets

L1-RT (LINE-1 reverse transcriptase)

Beyond the preview

Go deeper on LINE-1 retrotransposon vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LINE-1 retrotransposon vaccine.

Explore the full profile